Hot debate on right to read Marrakesh Treaty in European Parliament plenary The heat has been turned up on the EU Council of Member States to reach a solution for ratification of the Marrakesh Treaty for Visually-Impaired persons. Last night´s…
Author: david
Questions and requests for EP Plenary debate on Marrakesh Treaty
EUROPEAN PARLIAMENT PLENARY DEBATE ON MARRAKECH TREATY QUESTIONS FOR COUNCIL ON MARRAKECH TREATY RATIFICTION -Will the Council set a timetable for speedy ratification? -Does the Council agree that a “mixed ratification” would take years, and that such a delay…
Adapting medicines to the market or to patients’ needs?
By Yannis Natsis, 22 April 2015 (Views do not necessarily represent TACD positions) One has to analyse the future landscape and challenges that the European pharmaceutical industry is facing to better comprehend the political developments in medicines unfolding at the…
Greek Health Minister calls for public interest pharma model
Main speaking points of the Greek Health Minister Mr. Panayotis KOUROUMPLIS at the informal EU Health Ministers’ Council in Riga, Latvia (20-21 April 2015)1 The sustainability of the public health system accessible to all is a shared goal. Therefore,…
Write to your MEP to speak out for EU Marrakesh Treaty Ratification
Dear MEP: I would like to call your attention to the plenary debate on the ratification of the Marrakesh Treaty that will take place next session in Strasbourg, probably on April 29th. We would like to ask you to request…
Marrakesh in the EU: facing the excuses and delay tactics after Council statement What the Council Statement on Marrakech says: Council Statement: http://www.statewatch.org/news/2015/apr/eu-council-marrakesh-treaty-guidance-7321-15.pdf Two separate issues are dealt with: how to put Marrakesh into EU law and how to ratify…
Pharma is moving fast: What is coming up in pharmaceuticals in Europe
by Yannis Natsis (17/03/2015) (Views do not necessarily represent TACD positions) I recently attended a seminar in Brussels on medical innovation beautifully hosted by an important pharmaceutical company. As always, the setting was ideal. Fancy 5 star hotel, delicious buffet…
Guessing for medicine patents, TTIP and ISDS in action
Big pharmaceutical companies sometimes try to flout evidence-based innovation when they attempt to claim patents for wildly different illnesses with the same medicine and then sue the state with TTIP-like “investor protection” mechanisms if their patent applications are denied.…
Is it really worth pushing for EU medicine joint procurement?
Is it really worth pushing for? Access to medicines in Europe today & the Joint Procurement Agreement proposed by the European Commission. Policy recommendations & summary of views on the Joint Procurement Agreement (henceforth JPA) following talks with European…
European Commission and Council´s new “Pharmish” terms on access to medicines
(Views do not necessarily represent TACD positions) When “access” is not accessible, “transparency” is not transparent and “affordability” is not affordable Last Wednesday evening at the Strasbourg plenary session many Members of the European Parliament voiced their demands for an…